

13  
CLAIMS

BEST AVAILABLE COPY  
I

1. Peptide of formula:  
X-His-Asn-Pro-Y

in which:

X represents a Gln or pyro-Glu residue,  
Y represents a OH group or a residue of a basic amino acid.

2. Peptide according to Claim 1, in which Y is a Lys or Arg residue.

3. Peptide of formula:  
Gln-His-Asn-Pro<sub>12</sub>

II

4. Peptide of formula:  
pyro-Glu-His-Asn-Pro

III

5. Peptide of formula:  
Gln-His-Asn-Pro-Arg

IV

6. Peptide of formula:  
pyro-Glu-His-Asn-Pro-Arg

V

7. Peptide of formula:  
Gln-His-Asn-Pro-Lys

VI

8. Peptide of formula:  
pyro-Glu-His-Asn-Pro-Lys

VII

9. Polypeptide of formula:

1  
Met Lys Ser Leu Tyr Leu Ile Phe Gly Leu Trp Ile Leu  
20  
Leu Ala Cys Phe Gln Ser Gly Glu Gly Val Arg Gly Pro  
30  
Arg Arg Gln His Asn Pro Arg Arg Gln Gln Asp Pro Ser  
40  
Thr Leu Pro His Tyr Leu Gly Leu Gln Pro Asp Pro Asn  
50  
Gly Gly Gln Ile Gly Val Thr Ile Thr Ile Pro Leu Asn  
60  
Leu Gln Pro Pro Arg Val Leu Val Asn Leu Pro Gly Phe  
70  
Ile Thr Gly Pro Pro Leu Val Val Gln Gly Thr Thr Glu  
80  
90  
100

## 14 BEST AVAILABLE COPY

Tyr Gln Tyr Gln Trp Gln Leu Thr Ala Pro Asp Pro Thr

110

Pro Leu Ser Asn Pro Pro Thr Gln Leu His Ser Thr Glu

120

130

Gln Ala Asn Thr Lys Thr Asp Ala Lys Ile Ser Asn Thr

140

Thr Ala Thr Thr Gln Asn Ser Thr Asp Ile Phe Glu Gly

Gly Gly Lys

and derivatives of this polypeptide.

10. Monoclonal and polyclonal antibodies directed against a peptide or polypeptide according to any one of the Claims 1 to 9.

11. Hybridomas characterized in that they produce monoclonal antibodies according to Claim 10.

12. Assay or detection procedure for a peptide according to any one of the Claims 1 to 8, comprising the utilization of monoclonal antibodies directed against these peptides.

13. Assay procedure for a polypeptide according to Claim 9, comprising the utilization of monoclonal antibodies directed against this polypeptide.

14. Therapeutic composition containing a peptide or a polypeptide according to any one of the Claims 1 to 9.

ADD B3